Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Entrada Therapeutics Inc
(NQ:
TRDA
)
16.43
+0.32 (+1.96%)
Streaming Delayed Price
Updated: 3:28 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
54,209
Open
16.35
Bid (Size)
16.41 (4)
Ask (Size)
16.46 (1)
Prev. Close
16.11
Today's Range
15.99 - 16.64
52wk Range
10.75 - 18.17
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+8.27%
+8.27%
1 Month
-4.39%
-4.39%
3 Month
+9.35%
+9.35%
6 Month
+24.06%
+24.06%
1 Year
-0.15%
-0.15%
More News
Read More
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Recap: Entrada Therapeutics Q4 Earnings
March 13, 2024
Via
Benzinga
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 11, 2024
Via
Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
April 11, 2024
Via
Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
March 22, 2024
Via
Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
November 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 23, 2023
Via
Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
November 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 22, 2023
Via
Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.